Advertisement

Antianxiety Drugs: Clinical use in Psychiatry

  • Karl Rickels
  • Robert W. Downing
  • Andrew Winokur

Abstract

Each year, millions of patients visit physicians seeking relief from tensions, fears, worries, anxieties, and depression. Most physicians have found psychopharmacological agents, prescribed within the context of supportive, ventilating, or nonexploratory, as well as dynamic and insight-oriented psychotherapy, most useful for alleviating these disturbing emotions. Psychopharmacological agents do not, of course, represent a panacea for all neurotic ills. They do not, for example, directly affect the psychodynamic and environmental factors responsible for emotional problems; they do not directly affect the characterological or personality side of the patient (Joyce, 1971). By relieving the symptoms of anxiety, tension, and depression, however, they often render a patient less miserable and able to cope with intrapsychic and extrapsychic stress more appropriately.

Keywords

Psychotropic Drug Anxious Patient Interpersonal Sensitivity Nonspecific Factor Hopkins Symptom Checklist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bailey, D. W., and Fenichel, G. M., 1968, The treatment of prolonged seizure activity with intravenous diazepam, J. Pediatr.73:923–927.PubMedCrossRefGoogle Scholar
  2. Balter, M. B., and Levine, J., 1969, The nature and extent of psychotropic drug usage in the United States, Psychopharmacol. Bull.5:3–13.PubMedGoogle Scholar
  3. Benson, W. H., 1971, Comparative evaluation of diazepam (Valium) and phenobarbital for the relief of anxiety-related symptoms in patients hospitalized for acute myocardial infarction, J. Med. Assoc. Ga.60:276–278.PubMedGoogle Scholar
  4. Berger, F. M., 1963, The similarities and differences between meprobamate and barbiturates, Clin. Pharmacol. Ther.4:209–231.PubMedGoogle Scholar
  5. Berger, F. M., 1967, The role of drugs in suicide, in: Symposium on Suicide (L. Yochelson, ed.), pp. 117–132, George Washington University, Washington, D.C.Google Scholar
  6. Blackwell, B., 1973, Psychotropic drugs in use today: The role of diazepam in medical practice, J. Am. Med. Assoc.225:1637–1641.CrossRefGoogle Scholar
  7. Byck, R., 1975, Drugs and the treatment of psychiatric disorders, in: The Pharmacological Basis of Therapeutics, 5th ed. (L. S. Goodman and A. Gilman, eds.), p. 188, Macmillan, New York.Google Scholar
  8. Carter, S., and Gold, A. P., 1969, The critically ill child: Management of status epilepticus, Pediatrics44:732–733.PubMedGoogle Scholar
  9. Cazort, R. J., 1964, Role of relaxants in the treatment of traumatic musculoskeletal disorders: A double-blind study of three agents, Curr. Ther. Res.6:454–458.PubMedGoogle Scholar
  10. Cooper, A. J., Magnus, R. V., Rose, M., Phanjoo, A., Lancaster, N. P., Pollard, P., and Knowlson, P., 1973, Controlled trial of dipotassium chlorazepate (‘Tranxene’) in anxiety, Br. J. Psychiatry123:475–476.PubMedCrossRefGoogle Scholar
  11. Covi, L., Lipman, R. S., Pattison, J. H., Derogatis, L. R., and Uhlenhuth, E. H., 1973, Length of treatment with anxiolytic sedatives and response to their sudden withdrawal, Acta Psychiatr. Scand.49:51–64.PubMedCrossRefGoogle Scholar
  12. Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., and Covi, L., 1974, The Hopkins Symptom Checklist (HSCL): A measure of primary symptom dimensions, in: Psychological Measurements in Psychopharmacology, Modern Problems in Pharmacopsychiatry, Vol. 7 (P. Pichot, ed.), pp. 79–110, Karger, Basel.Google Scholar
  13. DiMascio, A., Shader, R. I., and Harmatz, J., 1969, Psychotropic drugs and induced hostility, Psychosomatics10:46–47.Google Scholar
  14. Dunbar, R. W., Boettner, R. B., Haley, J. V., Hall, V. E., and Morrow, D. H., 1971, The effect of diazepam on the antiarrhythmic response to lidocaine, Anesth. Analg.50:685–692.PubMedCrossRefGoogle Scholar
  15. Goldberg, H. L., and Finnerty, R. J., 1977, A double-blind study of prazepam vs. placebo in single doses in the treatment of anxiety. Compr. Psychiatry18:147–156.PubMedCrossRefGoogle Scholar
  16. Greenblatt, D. J., and Shader, R. L, 1974a, The treatment of alcoholism and other drug-dependent states, in: Benzodiazepines in Clinical Practice (D. J. Greenblatt and R. I. Shader, eds.), pp. 217–229, Raven Press, New York.Google Scholar
  17. Greenblatt, D. J., and Shader, R. I., 1974, Benzodiazepines in Clinical Practice, Raven Press, New York.Google Scholar
  18. Greenblatt, D. J., Shader, R. I., and Koch-Weser, J., 1975, Flurazepam hydrochloride, Clin. Pharmacol. Ther.17:1–14.PubMedGoogle Scholar
  19. Hackett, T. P., and Cassem, N. H., 1972, Reduction of anxiety in the coronary-care unit: A controlled double-blind comparison of chlordiazepoxide and amobarbital, Curr. Ther. Res.14:649–656.PubMedGoogle Scholar
  20. Hamilton, M., 1959, The assessment of anxiety states by rating, Br. J. Med. Psychol.32:50–55.PubMedCrossRefGoogle Scholar
  21. Hesbacher, P. T., Rickels, K., Gordon, P. E., Gray, B., Meckelnburg, R., Weise, C. C., and Vandervort, W. J., 1970a, Setting, patient, and doctor effects on drug response in neurotic patients: I. Differential attrition, dosage deviation and side reaction responses to treatment,Psychopharmacologia(Berlin)18:180–208.CrossRefGoogle Scholar
  22. Hesbacher, P. T., Rickels, K., Hutchison, J., Raab, E., Sablosky, L., Whalen, E. M., and Phillips, F. J., 1970b, Setting, patient, and doctor effects on drug response in neurotic patients: II. Differential improvement, Psychopharmacologia (Berlin)18:209–226.CrossRefGoogle Scholar
  23. Hesbacher, P. T., Rickels, K., Rial, W. Y., Segal, A., and Zamostien, B. B., 1976, Psychotropic drug prescription in family practice Compr. Psychiatry17:607–615.PubMedCrossRefGoogle Scholar
  24. Hollister, L. E., 1966, Overdoses of psychotherapeutic drugs, Clin. Pharmacol. Ther.7:142–146.PubMedGoogle Scholar
  25. Hollister, L. E., and Glazener, F. S., 1960, Withdrawal reactions from meprobamate, alone and combined with promazine: A controlled study, Psychopharmacologia1:336–341.PubMedCrossRefGoogle Scholar
  26. Hollister, L. E., Motzenbecker, F. P., and Degan, R. O., 1961, Withdrawal reactions from chlordiazepoxide (“Librium”), Psychopharmacologia2:63–68.PubMedCrossRefGoogle Scholar
  27. Hollister, L. E., Overall, J. E., Shelton, J., Pennington, V., Kimbell, I., and Johnson, M., 1967, Drug therapy of depression, Arch. Gen. Psychiatry17:486–493.PubMedCrossRefGoogle Scholar
  28. Hollister, L. E., Overall, J. E., Pokorny, A. D., and Shelton, J., 1971, Acetophenazine and diazepam in anxious depressions, Arch. Gen. Psychiatry24:273–278.PubMedCrossRefGoogle Scholar
  29. Jenner, F. A., and Parkin, D., 1961, A large overdose of chlordiazepoxide, Lancet2:322–323.CrossRefGoogle Scholar
  30. Joyce, C. R. B., 1971, Can drugs affect personality? in: Ciba Foundation Symposium on Personality and Science (I. T. Ramsey and R. Porter, eds.), pp. 65–72, Churchill Livingstone, London.Google Scholar
  31. Kaim, S. C., Klett, C. J., and Rothfeld, B., 1969, Treatment of the acute alcohol withdrawal state, a comparison of four drugs, Am. J. Psychiatry125:1640–1646.PubMedGoogle Scholar
  32. Kielholz, P., Goldberg, L., Obersteg, J., Poeldinger, W., Ramseyer, A., and Schmid, P., 1967, Circulation routière, tranquillisants et alcohol, Hyg. Ment.2:39–60.Google Scholar
  33. Kisson, M. D., 1965, Management of psychomotor agitation in acute alcoholism. A double-blind study using chlordiazepoxide, Dis. Nerv. Syst.26:364–368.Google Scholar
  34. Klein, D. F., 1964, Delineation of two drug-responsive anxiety syndromes, Psychopharmacologia5:397–408.PubMedCrossRefGoogle Scholar
  35. Klerman, G. L., 1974, Psychotropic drugs as therapeutic agents, Hastings Cent. Stud.2(1):81–93.PubMedCrossRefGoogle Scholar
  36. Klerman, G. L., DiMascio, A., Weissman, M., Prusoff, B., and Paykel, E. S., 1974, Treatment of depression by drugs and psychotherapy, Am. J. Psychiatry131:186–191.PubMedGoogle Scholar
  37. Lader, M., 1974, The peripheral and central role of the catecholamines in the mechanisms of anxiety, Int. Pharmacopsychiatry9:125–137.PubMedGoogle Scholar
  38. Linnoila, M., and Häkkinen, S., 1974, Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving, Clin. Pharmacol. Ther.15:368–373.PubMedGoogle Scholar
  39. Lipman, R. S., Covi, L., Rickels, K., Uhlenhuth, E. H., and Lazar, R., 1968, Selected measures of change in outpatient drug evaluation, in: Psychopharmacology: A Review of Progress, 1957–1967 (D. H. Efron, J. O. Cole, J. Levine, and J. R. Wittenborn, eds.), pp. 249–254, Public Health Service Publication No. 1836, Washington, D.C.Google Scholar
  40. Lipman, R. S., Uhlenhuth, E. H., Rickels, K., and Covi, L., 1969, Medication attitudes and drug response, Dis. Nerv. Syst.30:454–459.Google Scholar
  41. McMillin, W. P., 1973, Oxprenolol in anxiety, Lancet1:1193.PubMedCrossRefGoogle Scholar
  42. Overall, J. E., Hollister, L. E., Meyer, F., Kimbell, I., and Shelton, J., 1964, Imipramine and thioridazine in depressed and schizophrenic patients, J. Am. Med. Assoc.189:605–608.CrossRefGoogle Scholar
  43. Ramsay, I., Greer, S., et al. Bagley, C., 1973, Propranolol in neurotic and thyrotoxic anxiety, Br. J. Psychiatry122:555–560.PubMedCrossRefGoogle Scholar
  44. Rickels, K., 1968, Antineurotic agents: Specific and non-specific effects, in: Psychopharmacol-ogy: A Review of Progress, 1957–1967 (D. H. Efron, J. O. Cole, J. Levine, and J. R. Wittenborn, eds.), pp. 231–247, Public Health Service Publication No. 1836, Washington, D.C.Google Scholar
  45. Rickels, K., and Downing, R. W., 1974, Chlordiazepoxide and hostility in anxious outpatients, Am. J. Psychiatry131:442–444.PubMedGoogle Scholar
  46. Rickels, K., and Hesbacher, P. T., 1973, Over-the-counter daytime sedatives: A controlled study, J. Am. Med. Assoc.223:29–33.CrossRefGoogle Scholar
  47. Rickels, K., and Howard, K., 1970, The physician questionnaire: A useful tool in psychiatric drug research, Psychopharmacologia17:338–344.PubMedCrossRefGoogle Scholar
  48. Rickels, K., Lipman, R. S., and Raab, E., 1966, Previous medication, duration of illness and placebo response, J. Nerv. Ment. Dis.142:548–554.PubMedCrossRefGoogle Scholar
  49. Rickels, K., Raab, E., DeSilverio, R., and Etemad, B., 1967, Drug treatment in depression: Antidepressant or tranquilizer? J. Am. Med. Assoc.201:675–681.CrossRefGoogle Scholar
  50. Rickels, K., Sablosky, H., Silverman, H., Case, W. G., Rial, W., Mirman, M., and Gottlieb, S., 1977, Prazepam in anxiety: A controlled clinical trial, Compr. Psychiatry18:239–249.PubMedCrossRefGoogle Scholar
  51. Rickels, K., Garcia, C.-R., and Fisher, E., 1971a, A measure of emotional distress in private gynecologic practice, Obstet. Gynecol.38:139–146.Google Scholar
  52. Rickels, K., Lipman, R. S., Park, L. C., Covi, L., Uhlenhuth, E. H., and Mock, J. E., 1971b, Drug, doctor warmth, and clinic setting in the symptomatic response to minor tranquilizers, Psychopharmacologia20:128–152.CrossRefGoogle Scholar
  53. Rickels, K., Chung, H. R., Feldman, H. S., Gordon, P. E., Kelly, E. A., and Weise, C. C., 1973, Amitriptyline, diazepam, and phenobarbital sodium in depressed outpatients, J. Nerv. Ment. Dis.157:442–451.PubMedCrossRefGoogle Scholar
  54. Rickels, K., Pereira-Ogan, J. A., Case, W. G., Csanalosi, I., Mirman, M. J., Nathanson, J. E., and Parish, L. C., 1974, Chlormezanone in anxiety: A drug rediscovered? Am. J. Psychiatry131:592–595.PubMedGoogle Scholar
  55. Rickels, K., Gingrich, R. L., Morris, R. J., Rosenfeld, H., Perloff, M. M., Clark, E. L., and Schilling, A., 1975, Triazolam in insomniac family practice patients, Clin. Pharmacol. Ther.18:315–324.PubMedGoogle Scholar
  56. Uhlenhuth, E. H., Rickels, K., Fisher, S., Park, L. C., Lipman, R. S., and Mock, J., 1966, Drug, doctor’s verbal attitude and clinic setting in the symptomatic response to pharmacotherapy, Psychopharmacologia9:392–418.PubMedCrossRefGoogle Scholar
  57. Uhlenhuth, E. H., Duncan, D. B., and Park, L. C., 1969, Some nonpharmacologic modifiers of the response to Imipramine in depressed psychoneurotic outpatients: A confirmatory study, in: Psychotropic Drug Response: Advances in Prediction (P.R.A. May and J. R. Wittenborn, eds.), pp. 155–197, Charles C. Thomas, Springfield, Illinois.Google Scholar
  58. Uhlenhuth, E. H., Lipman, R. S., Balter, M. B., and Stern, M., 1974, Symptom intensity and life stress in the city, Arch. Gen. Psychiatry31:759–764.PubMedCrossRefGoogle Scholar
  59. Wheatley, D., 1969a, Comparative effects of propranolol and chlordiazepoxide in anxiety states, Br. J. Psychiatry115:1411–1412.CrossRefGoogle Scholar
  60. Wheatley, D., 19696, A comparative trial of imipramine and phenobarbital in depressed patients seen in general practice, J. Nerv. Ment. Dis.148:542–549.Google Scholar
  61. Wheatley, D., 1973, Psychopharmacology in Family Practice, William Heinemann Medical Books, London.Google Scholar
  62. Wickstrom, J., and Haddad, R., 1962, An evaluation of the muscle relaxant properties of chlordiazepoxide: A double-blind study, Am. J. Med. Sci.244:23–29.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Karl Rickels
    • 1
  • Robert W. Downing
    • 1
  • Andrew Winokur
    • 1
  1. 1.Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations